Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HX008 plus chemotherapy versus pembrolizumab plus chemotherapy as first-line treatment for advanced or metastatic nonsquamous NSCLC
CTR20202387Phase 2Completed
- Sponsor
- Taizhou Hanzhong Biomedical
- Start
- Sep 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pucotenlimab, pembrolizumab, pemetrexed, cisplatin, carboplatin in non-small cell lung cancer (NSCLC), sponsored by Taizhou Hanzhong Biomedical. Started Sep 2020; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20202387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202387.